NCT04126200 - Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) | Biotech Hunter

Enrollment

209

Participants

Timeline

Start Date

October 7, 2019

Primary Completion Date

February 12, 2029

Study Completion Date

February 12, 2029

Conditions

Multiple Myeloma

Interventions

DRUG

Belantamab mafodotin

Belantamab mafodotin will be administered.

DRUG

GSK3174998

GSK3174998 will be administered.

DRUG

Feladilimab

feladilimab will be administered.

DRUG

Nirogacestat

Nirogacestat will be administered.

DRUG

Dostarlimab

Dostarlimab will be administered.

DRUG

Isatuximab

Isatuximab will be administered.

DRUG

Lenalidomide

Lenalidomide will be administered.

DRUG

Dexamethasone

Dexamethasone will be administered.

DRUG

Pomalidomide

Pomalidomide will be administered.

Trial Locations (40)

3000

GSK Investigational Site, Melbourne

3065

GSK Investigational Site, Fitzroy

11528

GSK Investigational Site, Athens

20246

GSK Investigational Site, Hamburg

21565

GSK Investigational Site, Incheon

24105

GSK Investigational Site, Kiel

28027

GSK Investigational Site, Madrid

28040

GSK Investigational Site, Madrid

28041

GSK Investigational Site, Madrid

28223

GSK Investigational Site, Pozuelo de AlarcOn Madr

30322

GSK Investigational Site, Atlanta

31008

GSK Investigational Site, PamplonaNavarra

44033

GSK Investigational Site, Ulsan

46202

GSK Investigational Site, Indianapolis

49546

GSK Investigational Site, Grand Rapids

53792

GSK Investigational Site, Madison

59037

GSK Investigational Site, Lille

60590

GSK Investigational Site, Frankfurt

94805

GSK Investigational Site, Villejuif

125284

GSK Investigational Site, Moscow

02215

GSK Investigational Site, Boston

90110-270

GSK Investigational Site, Porto Alegre

41253-190

GSK Investigational Site, Salvador

04537-080

GSK Investigational Site, São Paulo

V5Z1M9

GSK Investigational Site, Vancouver

B3H 1V7

GSK Investigational Site, Halifax

M5G 2M9

GSK Investigational Site, Toronto

04103

GSK Investigational Site, Leipzig

01330

GSK Investigational Site, Mexico City

8934 AD

GSK Investigational Site, Leeuwarden

3584 CX

GSK Investigational Site, Utrecht

0450

GSK Investigational Site, Oslo

40-519

GSK Investigational Site, Katowice

20-081

GSK Investigational Site, Lublin

03080

GSK Investigational Site, Seoul

06351

GSK Investigational Site, Seoul

06591

GSK Investigational Site, Seoul

08916

GSK Investigational Site, Badalona

SE-791 82

GSK Investigational Site, Falun

SE-141 86

GSK Investigational Site, Stockholm